BMT CTN Protocol 1302

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma.

Below are protocol-related documents, which may be periodically updated.

            Protocol Co-Chair: Parameswaran Hari, MD

            Protocol Co-Chair: Taiga Nishihori, MD

            Protocol Co-Chair: Qaiser Bashir, MD (713-794-4422)

            Protocol Officer: Marcelo Pasquini, MD

            Protocol Coordinator: Dylan Mawby (301-251-1161)

            Medical Monitor: Dianna Howard, MD

The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study. The protocol closed to enrollment on September 14, 2018.